VEGFA - vascular endothelial growth factor A Gene

Also Known as VPF; VEGF; VEGF-A; eVEGF120; eVEGF164

Species: Bos taurus

Gene Type: protein coding
Gene ID: 281572

Summary

This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. It is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. [provided by RefSeq, Nov 2015]

VEGFA Products (5)

mRNA Protein Name
NM_001316955.1 NP_001303884.1 vascular endothelial growth factor A isoform VEGF-Ax precursor
NM_001316956.1 NP_001303885.1 vascular endothelial growth factor A isoform 4 precursor
NM_001316992.1 NP_001303921.1 vascular endothelial growth factor A isoform 3 precursor
NM_001316993.1 NP_001303922.1 vascular endothelial growth factor A isoform 2 precursor
NM_174216.2 NP_776641.1 vascular endothelial growth factor A isoform VEGF-A precursor
Protein Preferred Names Protein Names

vascular endothelial growth factor A

  • vascular endothelial growth factor 164

  • vascular permeability factor

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive MoleculesInhibitory Antibodies (4)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P9906 Bevacizumab Inhibitor ≥99.0% Unkown
HY-P9906A Bevacizumab (Anti-VEGFA) Inhibitor 99.07% Unkown
HY-P99116 Faricimab Inhibitor 97.97% Unkown
HY-P9973 Brolucizumab Inhibitor 99.90% Unkown

Clinical Phase

Bioactive Molecules (5)
Cat. No. Product Name Effect
Purity Phase
HY-P10284 S7 98.25% Phase 4
HY-B1788 Taurocholic acid 99.83% Phase 2
HY-N0545 Taurocholic acid sodium Agonist 99.82% Phase 2
HY-P3369 Gersizangitide 97.16% Phase 2
HY-B1788R Taurocholic acid (Standard) 99.91% Phase 2
Bioactive MoleculesInhibitory Antibodies (12)
Cat. No. Product Name Effect
Purity Phase
HY-P99675 Ivonescimab Inhibitor 99.13% Phase 4
HY-P99830 Conbercept Inhibitor 98.42% Phase 4
HY-P991097 Pumitamig Inhibitor 99.6% Phase 3
HY-P99576 Tarcocimab Inhibitor 98.35% Phase 3
HY-P991033 Tovecimig 97.39% Phase 3
HY-P990082 Suvemcitug Inhibitor 96% Phase 3
HY-P991416 BAT5906 Inhibitor / Phase 3
HY-P991418 MW02 Inhibitor / Phase 3
HY-P99330 Vanucizumab Inhibitor 95.12% Phase 2
HY-P991738 LM-299 Inhibitor 95.78% Phase 2
HY-P990689 Zifibancimig Inhibitor 99.00% Phase 2
HY-P991417 LYN00101 Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (37)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-10799 EG00229 trifluoroacetate Antagonist 98.03% Unkown
HY-117661 SPHINX31 Inhibitor 99.25% Unkown
HY-B1131 Taurocholic acid sodium salt hydrate 98.51% Unkown
HY-N2187 Deoxyshikonin 99.96% Unkown
HY-124593 PTC299 Inhibitor 99.71% Unkown
HY-144707 AK-778-XXMU 99.96% Unkown
HY-P10831 GNQWFI Antagonist 99.45% Unkown
HY-115746 Dimethyl-bisphenol A Inhibitor 99.78% Unkown
HY-N7043 Isosilybin A 99.63% Unkown
HY-N0545R Taurocholic acid sodium (Standard) Agonist 97.91% Unkown
HY-N10336 Notoginsenoside R4 99.90% Unkown
HY-138647 TGP-377/421 Inhibitor 98.17% Unkown
HY-W653842 Taurocholic acid-d8 sodium Agonist 98.83% Unkown
HY-101931 hVEGF-IN-1 Inhibitor 99.25% Unkown
HY-182700 NRPa-308 Inhibitor 98.96% Unkown
HY-P10971 Nef-M1 98.87% Unkown
HY-124722 OHM1 Inhibitor / Unkown
HY-149886 HIF-2α-IN-9 Inhibitor / Unkown
HY-163760 ZM-32 Inhibitor / Unkown
HY-168560 MMP Inhibitor 4 Inhibitor / Unkown
HY-176805 TGP-377 / Unkown
HY-179350 EG01449 Free acid Inhibitor / Unkown
HY-179350A EG01449 Inhibitor / Unkown
HY-182639 AM9928 Inhibitor / Unkown
HY-18333 EG00229 Inhibitor / Unkown
HY-N0545S2 Taurocholic acid-d4-1 sodium / Unkown
HY-N19872 Mukurozioside IIb / Unkown
HY-N19873 Mukurozioside IIa / Unkown
HY-P10550 VGB4 Antagonist / Unkown
HY-P3990 Coibamide A / Unkown
HY-RS15635 VEGFA Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-128446 CAY10781 Inhibitor 98.04% Unkown
HY-174510 Human VEGFA mRNA / Unkown
HY-B1788S2 Taurocholic acid-d5 / Unkown
HY-RS16537 Vegfa Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS22968 Vegfa Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W653893 Taurocholic acid-d5 sodium Agonist / Unkown
Bioactive MoleculesInhibitory Antibodies (8)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P9920A Ramucirumab (anti-VEGFR) Antagonist 99.9% Unkown
HY-P9951A Ranibizumab (anti-VEGF) Inhibitor 99.60% Unkown
HY-P990148 Anti-Mouse VEGF-A Antibody (2G11-2A05) Inhibitor 97.40% Unkown
HY-P992139 Valancitug Inhibitor 97.61% Unkown
HY-P991625 VX70 / Unkown
HY-P992323 BI-836880 Inhibitor / Unkown
HY-P992511 CS2009 Inhibitor / Unkown
HY-P992518 Pumitamig (Mouse IgG2a) Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens VEGFA NCBI NCBI:7422
Canis familiaris VEGFA NCBI NCBI:403802
Mus musculus VEGFA NCBI NCBI:22339
Susscrofa domestica VEGFA NCBI
Leporidae VEGFA NCBI
Rattus norvegicus VEGFA NCBI NCBI:83785